O
AGIO icon

OrbiMed’s Agios Pharmaceuticals AGIO Stock Holding History

OrbiMed’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100,000
Closed -$5.35M – 145
2020
Q2 		$5.35M Sell
100,000
-150,000
-60% -$6.95M 0.08% 119
2020
Q1 		$8.87M Buy
+250,000
New +$11.6M 0.15% 89

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed's AGIO Position: Q3 2025 in Review

OrbiMed sold out of Agios Pharmaceuticals (AGIO) in Q3 2025, closing a stake of 557,900 shares — an estimated $18.6M sold.

OrbiMed first reported a position in AGIO in Q1 2020 and held it in 8 quarters. The position peaked at $95.6M in Q4 2020. 220 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.

  • OrbiMed reported no remaining Agios Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • OrbiMed sold 557,900 Agios Pharmaceuticals shares in Q3 2025, an estimated $18.6M.
  • OrbiMed first reported a position in Agios Pharmaceuticals in Q1 2020 and held it in 8 quarters.
  • OrbiMed's Agios Pharmaceuticals position peaked at $95.6M in Q4 2020.
  • 220 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.